Related references
Note: Only part of the references are listed.Predictive Factors for Target Organ Injuries in Hypertensive Individuals
Manoel Paz Landim et al.
INTEGRATED BLOOD PRESSURE CONTROL (2021)
Multi-Target Approaches in Metabolic Syndrome
Felix F. Lillich et al.
FRONTIERS IN PHARMACOLOGY (2021)
Uncovering the signalling, structure and function of the 20-HETE-GPR75 pairing: Identifying the chemokine CCL5 as a negative regulator of GPR75
Jonathan Pascale et al.
BRITISH JOURNAL OF PHARMACOLOGY (2021)
A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions
Gemma A. Figtree et al.
CIRCULATION (2021)
Cardiac contractile dysfunction, during and following ischaemia, is attenuated by low-dose dietary fish oil in rats
Michael J. Macartney et al.
EUROPEAN JOURNAL OF NUTRITION (2021)
Effects of Epoxyeicosatrienoic Acid-Enhancing Therapy on the Course of Congestive Heart Failure in Angiotensin II-Dependent Rat Hypertension: From mRNA Analysis towards Functional In Vivo Evaluation
Petr Kala et al.
BIOMEDICINES (2021)
Cardiovascular disease burden: Italian and global perspectives
Andrea Saglietto et al.
MINERVA CARDIOLOGY AND ANGIOLOGY (2021)
Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics 2019 Lewis K. Dahl Memorial Lecture
John D. Imig et al.
HYPERTENSION (2020)
A Synthetic Epoxydocosapentaenoic Acid Analogue Ameliorates Cardiac Ischemia/Reperfusion Injury: The Involvement of the Sirtuin 3-NLRP3 Pathway
Ahmed M. Darwesh et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
The Role of Resolvins: EPA and DHA Derivatives Can Be Useful in the Prevention and Treatment of Ischemic Stroke
Nikola Tulowiecka et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Dual soluble epoxide hydrolase inhibitor/PPAR-γ agonist attenuates renal fibrosis
Anna Stavniichuk et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2020)
The Anti-Inflammatory and Antioxidant Properties of n-3 PUFAs: Their Role in Cardiovascular Protection
Francesca Oppedisano et al.
BIOMEDICINES (2020)
Soluble epoxide hydrolase inhibitors improve angiogenic function of endothelial progenitor cells via ERK/p38-mediated miR-126 upregulation in myocardial infarction mice after exercise
Yajun Gui et al.
EXPERIMENTAL CELL RESEARCH (2020)
Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Ren-2 Transgenic Rats
Jaroslav Hrdlicka et al.
FRONTIERS IN PHARMACOLOGY (2019)
Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats
Jan Neckar et al.
CLINICAL SCIENCE (2019)
The eicosapentaenoic acid:arachidonic acid ratio and its clinical utility in cardiovascular disease
J. R. Nelson et al.
POSTGRADUATE MEDICINE (2019)
Genetic Deletion or Pharmacological Inhibition of Soluble Epoxide Hydrolase Ameliorates Cardiac Ischemia/Reperfusion Injury by Attenuating NLRP3 Inflammasome Activation
Ahmed M. Darwesh et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Soluble epoxide hydrolase inhibitor, TUPS, attenuates isoproterenol/angiotensin II-induced cardiac hypertrophy through mammalian target of rapamycin-mediated autophagy inhibition
Huanji Zhang et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2019)
Cardioprotective effects of CYP-derived epoxy metabolites of docosahexaenoic acid involve limiting NLRP3 inflammasome activation
Ahmed M. Darwesh et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2019)
Pharmacological Blockade of Soluble Epoxide Hydrolase Attenuates the Progression of Congestive Heart Failure Combined With Chronic Kidney Disease: Insights From Studies With Fawn-Hooded Hypertensive Rats
Sarka Vackova et al.
FRONTIERS IN PHARMACOLOGY (2019)
A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes
Md Abdul Hye Khan et al.
DIABETOLOGIA (2018)
CYP2J2-derived EETs attenuated ethanol-induced myocardial dysfunction through inducing autophagy and reducing apoptosis
Chi Zhou et al.
FREE RADICAL BIOLOGY AND MEDICINE (2018)
Regulation of CYP2J2 and EET Levels in Cardiac Disease and Diabetes
Theresa Aliwarga et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severity of ischemic arrhythmias in rats with angiotensin II-dependent hypertension
Ludek Cervenka et al.
JOURNAL OF HYPERTENSION (2018)
Therapeutic potential of omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and inflammatory diseases
Wolf-Hagen Schunck et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics
John D. Imig
PHARMACOLOGY & THERAPEUTICS (2018)
Infarct size-limiting effect of epoxyeicosatrienoic acid analog EET-B is mediated by hypoxia-inducible factor-1 alpha via downregulation of prolyl hydroxylase 3
Jan Neckar et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2018)
Management of Measurable Variable Cardiovascular Disease' Risk Factors
Sonja Francula-Zaninovic et al.
CURRENT CARDIOLOGY REVIEWS (2018)
Orally Active Epoxyeicosatrienoic Acid Analogs
William B. Campbell et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2017)
Cytochrome P450-derived eicosanoids and heart function
K. Lockhart Jamieson et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Long-Term Administration of Eicosapentaenoic Acid Improves Post-Myocardial Infarction Cardiac Remodeling in Mice by Regulating Macrophage Polarization
Masayuki Takamura et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
The contribution of CYP2C gene subfamily involved in epoxygenase pathway of arachidonic acids metabolism to hypertension susceptibility in Russian population
Alexey Polonikov et al.
CLINICAL AND EXPERIMENTAL HYPERTENSION (2017)
Inhibitors of soluble epoxide hydrolase minimize ischemia-reperfusion-induced cardiac damage in normal, hypertensive, and diabetic rats
Oliul Islam et al.
CARDIOVASCULAR THERAPEUTICS (2017)
20-HETE Signals Through G-Protein-Coupled Receptor GPR75 (Gq) to Affect Vascular Function and Trigger Hypertension
Victor Garcia et al.
CIRCULATION RESEARCH (2017)
The ratio of serum n-3 to n-6 polyunsaturated fatty acids is associated with diabetes mellitus in patients with prior myocardial infarction: a multicenter cross-sectional study
Masao Takahashi et al.
BMC CARDIOVASCULAR DISORDERS (2017)
Molecular Mechanisms and New Treatment Paradigm for Atrial Fibrillation
Padmini Sirish et al.
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY (2016)
A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat
Md. Abdul Hye Khan et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2016)
Novel Roles of Epoxyeicosanoids in Regulating Cardiac Mitochondria
Haitham E. El-Sikhry et al.
PLOS ONE (2016)
Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice
Clothilde Roche et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2015)
Autophagy and oxidative stress in cardiovascular diseases
Yu Mei et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2015)
Epoxyeicosatrienoic Acids Regulate Macrophage Polarization and Prevent LPS-Induced Cardiac Dysfunction
Meiyan Dai et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2015)
EPA, not DHA, prevents fibrosis in pressure overload-induced heart failure: potential role of free fatty acid receptor 4
Julie A. Eclov et al.
JOURNAL OF LIPID RESEARCH (2015)
CYP epoxygenase 2J2 prevents cardiac fibrosis by suppression of transmission of pro-inflammation from cardiomyocytes to macrophages
Lei Yang et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2015)
Agonists of epoxyeicosatrienoic acids reduce infarct size and ameliorate cardiac dysfunction via activation of HO-1 and Wnt1 canonical pathway
Jian Cao et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2015)
CYP epoxygenase metabolites of docosahexaenoic acid protect HL-1 cardiac cells against LPS-induced cytotoxicity through SIRT1
V Samokhvalov et al.
CELL DEATH DISCOVERY (2015)
Inhibition of Soluble Epoxide Hydrolase Does Not Improve the Course of Congestive Heart Failure and the Development of Renal Dysfunction in Rats With Volume Overload Induced by Aorto-Caval Fistula
L. Cervenka et al.
PHYSIOLOGICAL RESEARCH (2015)
14,15-Epoxyeicosa-5,8,11-trienoic Acid (14,15-EET) Surrogates: Carboxylate Modifications
John R. Falck et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Epoxyeicosatrienoic acids and cardioprotection: The road to translation
Akinyemi Oni-Orisan et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2014)
N-3 polyunsaturated fatty acids decrease levels of doxorubicin-induced reactive oxygen species in cardiomyocytes - involvement of uncoupling protein UCP2
Hsiu-Ching Hsu et al.
JOURNAL OF BIOMEDICAL SCIENCE (2014)
Orally Active Epoxyeicosatrienoic Acid Analog Attenuates Kidney Injury in Hypertensive Dahl Salt-Sensitive Rat
Md. Abdul Hye Khan et al.
HYPERTENSION (2013)
Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction
Andrew R. Kompa et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Effect of Ischemia Reperfusion Injury and Epoxyeicosatrienoic Acids on Caveolin Expression in Mouse Myocardium
Ketul R. Chaudhary et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2013)
Epoxyeicosatrienoic Acid Pathway in Human Health and Diseases
Jeremy Bellien et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2013)
Roles of endothelial nitric oxide synthase (eNOS) and mitochondrial permeability transition pore (MPTP) in epoxyeicosatrienoic acid (EET)-induced cardioprotection against infarction in intact rat hearts
Garrett J. Gross et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2013)
Unique mechanistic insights into the beneficial effects of soluble epoxide hydrolase inhibitors in the prevention of cardiac fibrosis
Padmini Sirish et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease
Katherine N. Theken et al.
ATHEROSCLEROSIS (2012)
Novel soluble epoxide hydrolase inhibitor protects mitochondrial function following stress
Sri N. Batchu et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2012)
Epoxyeicosatrienoic Acids Contribute With Altered Nitric Oxide and Endothelin-1 Pathways to Conduit Artery Endothelial Dysfunction in Essential Hypertension
Jeremy Bellien et al.
CIRCULATION (2012)
Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension
Jan Neckar et al.
CLINICAL SCIENCE (2012)
Role of PI3Kα and sarcolemmal ATP-sensitive potassium channels in epoxyeicosatrienoic acid mediated cardioprotection
Sri N. Batchu et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2012)
EPOXIDES AND SOLUBLE EPOXIDE HYDROLASE IN CARDIOVASCULAR PHYSIOLOGY
John D. Imig
PHYSIOLOGICAL REVIEWS (2012)
Oxidative stress and heart failure
Hiroyuki Tsutsui et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2011)
Cardioprotective effect of a dual acting epoxyeicosatrienoic acid analogue towards ischaemia reperfusion injury
S. N. Batchu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Omega-3 Fatty Acids Prevent Pressure Overload-Induced Cardiac Fibrosis Through Activation of Cyclic GMP/Protein Kinase G Signaling in Cardiac Fibroblasts
Jinghai Chen et al.
CIRCULATION (2011)
Cytochrome P450 metabolites of arachidonic acid are elevated in stroke patients compared with healthy controls
Natalie C. Ward et al.
CLINICAL SCIENCE (2011)
Association between polymorphisms of CYP2J2 and EPHX2 genes and risk of coronary artery disease
Yujun Xu et al.
PHARMACOGENETICS AND GENOMICS (2011)
Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of STAT3 signaling
Matthias J. Merkel et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2010)
Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice
Craig R. Lee et al.
FASEB JOURNAL (2010)
Inhibition of Soluble Epoxide Hydrolase by trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid Is Protective Against Ischemia-Reperfusion Injury
Ketul R. Chaudhary et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2010)
Cardiovascular Disease Risk Factors: Epidemiology and Risk Assessment
Björn Dahlöf
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Endothelial Dysfunction as a Target for Prevention of Cardiovascular Disease
Daniele Versari et al.
DIABETES CARE (2009)
Epoxyeicosatrienoic acids limit damage to mitochondrial function following stress in cardiac cells
D. Katragadda et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2009)
Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches
Ning Li et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2009)
Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases
John D. Imig et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension
Marlina Manhiani et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2009)
Multiple antiapoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia
Anuradha Dhanasekaran et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2008)
Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart
Garrett J. Gross et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2008)
Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease
Jan Monti et al.
NATURE GENETICS (2008)
Characterization of epoxyeicosatrienoic acid binding site in U937 membranes using a novel radiolabeled agonist, 20-I-125-14,15-epoxyeicosa-8(Z)-enoic acid
Wenqi Yang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Evidence for association of polymorphisms in CYP2J2 and susceptibility to essential hypertension
Sheng-Nan Wu et al.
ANNALS OF HUMAN GENETICS (2007)
Characterization of 14,15-epoxyeicosatrienoyl-sulfonamides as 14,15-epoxyeicosatrienoic acid agonists: Use for studies of metabolism and ligand binding
Wenqi Yang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury
John M. Seubert et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2007)
Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors
Danyan Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function
John M. Seubert et al.
CIRCULATION RESEARCH (2006)
n-3 fatty acids and cardiovascular disease
Jan L. Breslow
AMERICAN JOURNAL OF CLINICAL NUTRITION (2006)
Long-chain polyunsaturated fatty acids protect the heart against ischemia/reperfusion-induced injury via a MAPK dependent pathway
AM Engelbrecht et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2005)
Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension
O Jung et al.
HYPERTENSION (2005)
Decreased renal cytochrome P4502C enzymes and impaired vasodilation are associated with angiotensin salt-sensitive hypertension
XY Zhao et al.
HYPERTENSION (2003)
Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension
JD Imig et al.
HYPERTENSION (2002)
Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease
T Heitzer et al.
CIRCULATION (2001)
Mechanism and signal transduction of 14 (R), 15 (S)-epoxyeicosatrienoic acid (14,15-EET) binding in guinea pig monocytes
PYK Wong et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2000)
Share Paper
